These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11025768)

  • 1. The effect of halofuginone, an inhibitor of collagen type i synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model.
    Nagler A; Gofrit O; Ohana M; Pode D; Genina O; Pines M
    J Urol; 2000 Nov; 164(5):1776-80. PubMed ID: 11025768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats.
    Bruck R; Genina O; Aeed H; Alexiev R; Nagler A; Avni Y; Pines M
    Hepatology; 2001 Feb; 33(2):379-86. PubMed ID: 11172339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of halofuginone in limiting urethral stricture formation and recurrence: an experimental study in rabbits.
    Jaidane M; Ali-El-Dein B; Ounaies A; Hafez AT; Mohsen T; Bazeed M
    J Urol; 2003 Nov; 170(5):2049-52. PubMed ID: 14532851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Halofuginone--an inhibitor of collagen type I synthesis--prevents postoperative formation of abdominal adhesions.
    Nagler A; Rivkind AI; Raphael J; Levi-Schaffer F; Genina O; Lavelin I; Pines M
    Ann Surg; 1998 Apr; 227(4):575-82. PubMed ID: 9563549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth inhibition of prostate cancer xenografts by halofuginone.
    Gavish Z; Pinthus JH; Barak V; Ramon J; Nagler A; Eshhar Z; Pines M
    Prostate; 2002 May; 51(2):73-83. PubMed ID: 11948962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the prevention of esophageal strictures related to caustic injury.
    Ozçelik MF; Pekmezci S; Saribeyoğlu K; Unal E; Gümüştaş K; Doğusoy G
    Am J Surg; 2004 Feb; 187(2):257-60. PubMed ID: 14769315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model.
    Nagler A; Genina O; Lavelin I; Ohana M; Pines M
    Am J Obstet Gynecol; 1999 Mar; 180(3 Pt 1):558-63. PubMed ID: 10076128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.
    Zion O; Genin O; Kawada N; Yoshizato K; Roffe S; Nagler A; Iovanna JL; Halevy O; Pines M
    Pancreas; 2009 May; 38(4):427-35. PubMed ID: 19188864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Halofuginone-coated urethral catheters prevent periurethral spongiofibrosis in a rat model of urethral injury.
    Krane LS; Gorbachinsky I; Sirintrapun J; Yoo JJ; Atala A; Hodges SJ
    J Endourol; 2011 Jan; 25(1):107-12. PubMed ID: 21204688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone.
    Pines M; Domb A; Ohana M; Inbar J; Genina O; Alexiev R; Nagler A
    Biochem Pharmacol; 2001 Nov; 62(9):1221-7. PubMed ID: 11705455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone.
    Elkin M; Ariel I; Miao HQ; Nagler A; Pines M; de-Groot N; Hochberg A; Vlodavsky I
    Cancer Res; 1999 Aug; 59(16):4111-8. PubMed ID: 10463616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Halofuginone inhibits collagen deposition in fibrous capsules around implants.
    Olbrich KC; Meade R; Bruno W; Heller L; Klitzman B; Levin LS
    Ann Plast Surg; 2005 Mar; 54(3):293-6;discussion 296. PubMed ID: 15725837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin inhibits formation of urethral stricture in rabbits.
    Chong T; Fu DL; Li HC; Zhang HB; Zhang P; Gan WM; Wang ZM
    J Pharmacol Exp Ther; 2011 Jul; 338(1):47-52. PubMed ID: 21464336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Halofuginone reduces the occurrence of renal fibrosis in 5/6 nephrectomized rats.
    Benchetrit S; Yarkoni S; Rathaus M; Pines M; Rashid G; Bernheim J; Bernheim J
    Isr Med Assoc J; 2007 Jan; 9(1):30-4. PubMed ID: 17274353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of esophageal strictures in a caustic burn model using halofuginone, an inhibitor of collagen type I synthesis.
    Arbell D; Udassin R; Koplewitz BZ; Ohana M; Genina O; Pines M; Nagler A
    Laryngoscope; 2005 Sep; 115(9):1632-5. PubMed ID: 16148708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis.
    Pines M; Knopov V; Genina O; Lavelin I; Nagler A
    J Hepatol; 1997 Aug; 27(2):391-8. PubMed ID: 9288615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the prevention of pancreatic fibrosis in an experimental model of severe hyperstimulation and obstruction pancreatitis.
    Karatas A; Paksoy M; Erzin Y; Carkman S; Gonenc M; Ayan F; Aydogan F; Uzun H; Durak H
    J Surg Res; 2008 Jul; 148(1):7-12. PubMed ID: 18570924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis effect of halofuginone.
    Gnainsky Y; Spira G; Paizi M; Bruck R; Nagler A; Genina O; Taub R; Halevy O; Pines M
    Cell Tissue Res; 2006 Jun; 324(3):385-94. PubMed ID: 16508789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of halofuginone on fibrosis formation secondary to experimentally induced subglottic trauma.
    Ertuğrul EE; Cincik H; Dogru S; Cekin E; Berber U; Gungor A; Poyrazoğlu IE
    Laryngoscope; 2007 Feb; 117(2):299-302. PubMed ID: 17277625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone.
    Nagler A; Ohana M; Shibolet O; Shapira MY; Alper R; Vlodavsky I; Pines M; Ilan Y
    Eur J Cancer; 2004 Jun; 40(9):1397-403. PubMed ID: 15177499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.